Cart
sales@molnova.com
Enzaplatovir
CAS No. 1323077-89-9
Enzaplatovir( —— )
Catalog No. M34242 CAS No. 1323077-89-9
Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 327 | Get Quote |
|
| 5MG | 511 | Get Quote |
|
| 10MG | 825 | Get Quote |
|
| 25MG | 1398 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEnzaplatovir
-
NoteResearch use only, not for human use.
-
Brief DescriptionEnzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.
-
DescriptionEnzaplatovir (BTA-C585) is an orally bioavailable Inhibitor for respiratory syncytial virus (RSV) infection.
-
In VitroRespiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor.
-
In Vivo——
-
Synonyms——
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorRSV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1323077-89-9
-
Formula Weight377.4
-
Molecular FormulaC20H19N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 200 mg/mL (529.94 mM; Ultrasonic )
-
SMILESCc1nocc1C(=O)N1CCN2C(=O)c3cccn3C[C@]12c1ccc(C)nc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Eric A F Sim?es, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.?
molnova catalog
related products
-
Palivizumab
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
-
Nirsevimab
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection.
-
Stafia-1
Stafia-1 is a potent STAT5a inhibitor ( IC50=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.
